New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - omeprazole 20mg;   - modified release capsule - 20 mg - active: omeprazole 20mg   excipient: crospovidone gelatin hypromellose isopropyl alcohol magnesium stearate mannitol meglumine methacrylic acid - ethyl acrylate copolymer opacode black s-1-27794 poloxamer povidone purified water triethyl citrate

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - azacitidine 100mg - powder for injection - 100 mg - active: azacitidine 100mg excipient: mannitol - azacitidine is indicated for the treatment of patients with intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukaemia (cmmol [10-29 percent marrow blasts without myeloproliferative disorder]), and acute myeloid leukaemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib - dr. reddy's, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib - dr. reddy's as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib - dr. reddy's is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - omeprazole 10mg;   - modified release capsule - 10 mg - active: omeprazole 10mg   excipient: capsugel purple op.c046 capsugel yellow op.c305 crospovidone hypromellose isopropyl alcohol magnesium stearate mannitol meglumine methacrylic acid - ethyl acrylate copolymer opacode black s-1-27794 poloxamer povidone purified water triethyl citrate

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - sertraline hydrochloride 111.92mg equivalent to sertraline 100 mg - film coated tablet - 100 mg - active: sertraline hydrochloride 111.92mg equivalent to sertraline 100 mg excipient: calcium hydrogen phosphate colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry white oy-58900 polysorbate 80 sodium starch glycolate - sertraline is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - sertraline hydrochloride 55.96mg equivalent to sertraline 50 mg - film coated tablet - 50 mg - active: sertraline hydrochloride 55.96mg equivalent to sertraline 50 mg excipient: calcium hydrogen phosphate colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry white oy-58900 polysorbate 80 sodium starch glycolate - sertraline is indicated for the treatment of symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - bosentan monohydrate 129.082mg equivalent to bosentan 125 mg - film coated tablet - 125 mg - active: bosentan monohydrate 129.082mg equivalent to bosentan 125 mg excipient: ethylcellulose glycerol magnesium stearate maize starch opadry yellow 03k82318 povidone sodium starch glycolate starch - the medicine is indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - bosentan monohydrate 64.541mg equivalent to bosentan 62.5 mg - film coated tablet - 62.5 mg - active: bosentan monohydrate 64.541mg equivalent to bosentan 62.5 mg excipient: ethylcellulose glycerol magnesium stearate maize starch opadry yellow 03k82318 povidone sodium starch glycolate starch - the medicine is indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 116 mg (equivalent: dasatinib, qty 100 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; lactose; silicon dioxide; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin - dasatinib dr.reddy's is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib dr.reddy's is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 23.2 mg (equivalent: dasatinib, qty 20 mg) - tablet, film coated - excipient ingredients: lactose; croscarmellose sodium; triacetin; hydrogenated castor oil; magnesium stearate; titanium dioxide; silicon dioxide; microcrystalline cellulose; hypromellose - dasatinib dr.reddy's is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib dr.reddy's is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.